(Q43946040)

28 November 2017

CYP3A5 genotype has an impact on the metabolism of the HIV protease inhibitor saquinavir (English)

1 reference

28 November 2017

1 reference

5

1 reference

28 November 2017

8

1 reference

28 November 2017

10

1 reference

28 November 2017

11

1 reference

28 November 2017

Josephson F

1

1 reference

28 November 2017

Allqvist A

2

1 reference

28 November 2017

Janabi M

3

1 reference

28 November 2017

Sayi J

4

1 reference

28 November 2017

Jande M

6

1 reference

28 November 2017

Mahindi M

7

1 reference

28 November 2017

Bottiger Y

9

1 reference

28 November 2017

Bertilsson L

12

1 reference

28 November 2017

language of work or name

English

0 references

publication date

28 February 2007

1 reference

Clinical Pharmacology & Therapeutics

28 November 2017

1 reference

28 November 2017

81

1 reference

28 November 2017

5

1 reference

28 November 2017

708-712

1 reference

Significance of the minor cytochrome P450 3A isoforms.

28 November 2017

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100117

7 January 2021

Characterization of a cDNA encoding a new member of the glucocorticoid-responsive cytochromes P450 in human liver

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100117

7 January 2021

The genetic determinants of the CYP3A5 polymorphism

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100117

7 January 2021

CYP3A5 phenotype-genotype correlations in a British population

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100117

7 January 2021

Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100117

7 January 2021

Genetic findings and functional studies of human CYP3A5 single nucleotide polymorphisms in different ethnic groups

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100117

7 January 2021

CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100117

7 January 2021

Summary of information on human CYP enzymes: human P450 metabolism data

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100117

7 January 2021

CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100117

7 January 2021

The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100117

7 January 2021

Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100117

7 January 2021

Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100117

7 January 2021

Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100117

7 January 2021

Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100117

7 January 2021

Tacrolimus Dosing in Pediatric Heart Transplant Patients is Related to CYP3A5 and MDR1 Gene Polymorphisms

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100117

7 January 2021

Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100117

7 January 2021

CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100117

7 January 2021

The effect of variable CYP3A5 expression on cyclosporine dosing, blood pressure and long-term graft survival in renal transplant patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100117

7 January 2021

Genotype???phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100117

7 January 2021

Pharmacokinetics of midazolam and 1'-hydroxymidazolam in Chinese with different CYP3A5 genotypes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100117

7 January 2021

CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100117

7 January 2021

Association of the CYP3A5 A6986G (CYP3A5*3) polymorphism with saquinavir pharmacokinetics

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100117

7 January 2021

Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100117

7 January 2021

Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100117

7 January 2021

Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100117

7 January 2021

Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100117

7 January 2021

Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100117

7 January 2021

Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100117

7 January 2021

Enzymatic characteristics of CYP3A5 and CYP3A4: a comparison of in vitro kinetic and drug-drug interaction patterns.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100117

7 January 2021

Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100117

7 January 2021

CYP3A4, CYP3A5, and CYP3A43 genotypes and haplotypes in the etiology and severity of prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100117

7 January 2021

CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5'-promoter region polymorphism

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100117

7 January 2021

HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100117

7 January 2021

Highly sensitive determination of saquinavir in biological samples using liquid chromatography-tandem mass spectrometry

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100117

7 January 2021

Identifiers

DOI

10.1038/SJ.CLPT.6100117

1 reference

28 November 2017

1 reference